![Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy](https://www.jcancer.org/v12/p5365/toc.jpg)
Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy
![Neo Sphere (Six-Fours-les-Plages) | Avis, Emails, Dirigeants, Chiffres d'affaires, Bilans | 799545389 Neo Sphere (Six-Fours-les-Plages) | Avis, Emails, Dirigeants, Chiffres d'affaires, Bilans | 799545389](https://images.b-reputation.com/screenshot-website-https-neo-sphere-fr-2022-03-18-17-56-235869.jpg)
Neo Sphere (Six-Fours-les-Plages) | Avis, Emails, Dirigeants, Chiffres d'affaires, Bilans | 799545389
![Frontiers | Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment Frontiers | Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment](https://www.frontiersin.org/files/Articles/632357/fonc-11-632357-HTML-r2/image_m/fonc-11-632357-g001.jpg)
Frontiers | Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
![6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/e961d20e-ceaa-45ca-9a0e-9dcf5ad06ffe/gr1.gif)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet
![Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer ( NeoSphere): a randomised multicentre, open-label, phase 2 trial - The Lancet Oncology Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer ( NeoSphere): a randomised multicentre, open-label, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2005796767/2025322220/gr1.gif)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer ( NeoSphere): a randomised multicentre, open-label, phase 2 trial - The Lancet Oncology
![Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab - ScienceDirect Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419320654-gr1.jpg)
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab - ScienceDirect
![Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial - ScienceDirect Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419357266-gr1.jpg)
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial - ScienceDirect
![Frontiers | Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy Frontiers | Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy](https://www.frontiersin.org/files/Articles/592393/fonc-11-592393-HTML/image_m/fonc-11-592393-g001.jpg)
Frontiers | Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
![Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer ( NeoSphere) a randomised multicentre, open-label, phase 2 trial – OncoPrescribe Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer ( NeoSphere) a randomised multicentre, open-label, phase 2 trial – OncoPrescribe](http://www.oncoprescribe.com/app/uploads/_1395987978.jpg)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer ( NeoSphere) a randomised multicentre, open-label, phase 2 trial – OncoPrescribe
![Neo Sphere - Formation professionnelle, 60 av Joseph Raynaud, 83140 Six Fours les Plages (France) - Adresse, Horaire Neo Sphere - Formation professionnelle, 60 av Joseph Raynaud, 83140 Six Fours les Plages (France) - Adresse, Horaire](https://www.pagesjaunes.fr/media/agc/resize/227x400/89/c1/85/00/00/f4/4f/bd/4b/4d/5d3989c1850000f44fbd4b4d/5d3989c1850000f44fbd4b4e.jpg)
Neo Sphere - Formation professionnelle, 60 av Joseph Raynaud, 83140 Six Fours les Plages (France) - Adresse, Horaire
![PDF) Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial PDF) Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial](https://www.researchgate.net/profile/Eugenia-Galeota/publication/282045395/figure/tbl1/AS:667096144941061@1536059523490/NeoSphere-patients-characteristics_Q320.jpg)